These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8610821)

  • 21. Differential effects of haloperidol on negative symptoms in drug-naive schizophrenic patients: effects on plasma homovanillic acid.
    Labarca R; Silva H; Jerez S; Ruiz A; Forray MI; Gysling K; Andres ME; Bustos G; Castillo Y; Hono J
    Schizophr Res; 1993 Mar; 9(1):29-34. PubMed ID: 8461269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia.
    Angrist B; Rotrosen J; Gershon S
    Psychopharmacology (Berl); 1980; 72(1):17-9. PubMed ID: 6110217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
    Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
    Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute d-amphetamine challenge in schizophrenia: effects on cerebral glucose utilization and clinical symptomatology.
    Wolkin A; Sanfilipo M; Angrist B; Duncan E; Wieland S; Wolf AP; Brodie JD; Cooper TB; Laska E; Rotrosen JP
    Biol Psychiatry; 1994 Sep; 36(5):317-25. PubMed ID: 7993958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Zotepine: treatment of schizophrenic patients with predominantly negative symptoms. A double-blind study vs. haloperidol].
    Barnas C; Stuppäck CH; Miller C; Haring C; Sperner-Unterweger B; Fleischhacker WW
    Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():36-40. PubMed ID: 1683338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical correlates of decreased anteroposterior metabolic gradients in positron emission tomography (PET) of schizophrenic patients.
    DeLisi LE; Buchsbaum MS; Holcomb HH; Dowling-Zimmerman S; Pickar D; Boronow J; Morihisa JM; van Kammen DP; Carpenter W; Kessler R
    Am J Psychiatry; 1985 Jan; 142(1):78-81. PubMed ID: 3871312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of haloperidol challenge on regional cerebral glucose utilization in normal human subjects.
    Bartlett EJ; Brodie JD; Simkowitz P; Dewey SL; Rusinek H; Wolf AP; Fowler JS; Volkow ND; Smith G; Wolkin A
    Am J Psychiatry; 1994 May; 151(5):681-6. PubMed ID: 8166309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Negative symptoms and hypofrontality in chronic schizophrenia.
    Wolkin A; Sanfilipo M; Wolf AP; Angrist B; Brodie JD; Rotrosen J
    Arch Gen Psychiatry; 1992 Dec; 49(12):959-65. PubMed ID: 1360200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A controlled comparative study of chlorprothixene vs. haloperidol in chronic schizophrenia.
    Fux M; Belmaker RH
    Isr J Psychiatry Relat Sci; 1991; 28(1):37-40. PubMed ID: 1830565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients.
    Ko GN; Korpi ER; Kirch DG
    J Clin Psychopharmacol; 1989 Jun; 9(3):186-90. PubMed ID: 2661607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine.
    Kapur S; Roy P; Daskalakis J; Remington G; Zipursky R
    Am J Psychiatry; 2001 Feb; 158(2):311-4. PubMed ID: 11156818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
    Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
    Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia.
    Goldberg TE; Bigelow LB; Weinberger DR; Daniel DG; Kleinman JE
    Am J Psychiatry; 1991 Jan; 148(1):78-84. PubMed ID: 1984711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia.
    Wolkin A; Barouche F; Wolf AP; Rotrosen J; Fowler JS; Shiue CY; Cooper TB; Brodie JD
    Am J Psychiatry; 1989 Jul; 146(7):905-8. PubMed ID: 2568094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
    Harvey PD; Rabinowitz J; Eerdekens M; Davidson M
    Am J Psychiatry; 2005 Oct; 162(10):1888-95. PubMed ID: 16199835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients.
    Lee SM; Chou YH; Li MH; Wan FJ; Yen MH
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1101-7. PubMed ID: 17475386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cerebral cortical gray expansion associated with two second-generation antipsychotics.
    Garver DL; Holcomb JA; Christensen JD
    Biol Psychiatry; 2005 Jul; 58(1):62-6. PubMed ID: 15992524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
    Levinson I; Levine S
    Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667
    [No Abstract]   [Full Text] [Related]  

  • 40. [Effects of anti-psychotic agents on brain glucose metabolism and regional cerebral circulation in patients with schizophrenia-- study by functional brain imaging of SPECT and PET].
    Jibiki I
    Seishin Shinkeigaku Zasshi; 2002; 104(2):144-51. PubMed ID: 11985069
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.